Dr. Frans Van Andel

Dr. Frans van Andel has degrees in health economics (Universities of Groningen and Utrecht, NL), public health (Harvard School of Public Health, Boston, USA) and a PhD in pharmaceutical economics (Erasmus University Rotterdam.NL). Dr van Andel started his career in Basel, Switzerland where he worked in various functions as a health economist for Novartis AG, a global pharmaceutical company. He then switched to the public sector and worked a few years for WHO first at HQ in Geneva, Switzerland and later on as a Regional Adviser Pharmaceuticals at the WHO Europe office in Copenhagen, Denmark. More recently, Dr van Andel through his pan-European company PPI HC Ltd, has focussed on supporting startup and scaleup medtech companies with innovative products in pharma, medical devices and digital healthcare products achieving market access, pricing and reimbursement of their technologies. He is familiar with product life cycle management and the application of appropriate value assessment instruments (such as HTA, economic modelling and value based pricing) to assess the value of a medtech technology. Dr van Andel has worked for a multitude of organizations in the public and private sector in the EU, Central and Eastern Europe, Africa, Middle East and Asia. In addition to his activities in market access, Dr van Andel occasionally conducts evaluations of global health projects as a Team Leader on behalf of institutional agencies such as the European Union, the World Bank and the Netherlands' Government.